Ligand Pharma to acquire Apeiron Biologics
Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1201 entries already.
Entries by Thomas Gabrielczyk
EMA-Gate: PharmaMar wins suit against EMA
/in News/by Thomas GabrielczykThe European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
EuroscreenFast and GW Vitek announce distribution partnership in Korea
/in News/by Thomas GabrielczykBelgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.
EMA-Gate: PharmaMar wins suit against EMA
/in News/by Thomas GabrielczykThe European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
/in News/by Thomas GabrielczykDanish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx […]
Anacura aquires Ohmx.bio
/in News/by Thomas GabrielczykMerger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
Ten drug recommendations by EMA
/in News/by Thomas GabrielczykEMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.
Semarion Ltd. wins Ignite SME award at SLAS Europe
/in News/by Thomas GabrielczykUK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona. <br /><br /><br />
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
/in News/by Thomas GabrielczykUS pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones. <div></div>
SLAS Europe 2024 honours products with most impact
/in News/by Thomas GabrielczykSwiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.